SCHEMBL3370156

SCHEMBL3370156

Oc1ncc(Br)cc1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31149394 0.77
SCHEMBL1577316 0.77
SCHEMBL29520643 0.77
SCHEMBL621291 0.77
SCHEMBL502594 0.77
SCHEMBL29751880 0.77
SCHEMBL30421035 0.77
SCHEMBL8150851 0.77
SCHEMBL13972324 0.74
SCHEMBL20714876 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use AMGEN INC. (US) 2025-11-18 US disclosed
US-20250346593-A1 IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS INTERLINE THERAPEUTICS INC (US) 2025-11-13 US disclosed
EP-4134364-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2025-07-30 EP disclosed
US-20250179061-A1 RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2025-06-05 US disclosed
EP-4559525-A2 INHIBITING HUMAN INTEGRIN ALPHA4BETA7 Morphic Therapeutic, Inc. (US) 2025-05-28 EP disclosed
EP-4045039-B1 INHIBITING HUMAN INTEGRIN ALPHA4BETA7 MORPHIC THERAPEUTIC INC (US) 2025-04-23 EP disclosed
CN-119698416-A Imidazo (1, 2-A) pyridine derivatives as RIPK2 inhibitors 英特莱治疗公司 2025-03-25 CN disclosed
EP-4518974-A1 IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS Interline Therapeutics, Inc. (US) 2025-03-12 EP disclosed
EP-4486743-A1 RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2025-01-08 EP disclosed
CN-119192137-A Inhibition of human integrin alpha4β7 莫菲克医疗股份有限公司 2024-12-27 CN disclosed
US-20070203187-A1 Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof MERCK & CO., INC. (US) 2007-08-30 US disclosed
EP-1646629-A2 CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF Merck &amp; Co., Inc. (US) 2006-04-19 EP disclosed
US-20050038092-A1 Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof MERCK SHARP & DOHME CORP. 2005-02-17 US disclosed
WO-2005005398-A2 CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF MERCK & CO., INC. (US) 2005-01-20 WO disclosed
EP-0573878-B1 3-fluoropyridines, process for their preparation and their use in liquid crystal mixtures AVENTIS RES & TECH GMBH & CO (DE) 2000-12-20 EP disclosed
US-5445763-A Ferroelectricity; switching and/or display devices containing outer plates, electrodes, at least one polarizer and one alignment layer HOECHST AKTIENGESELLSCHAFT (DE) 1995-08-29 US disclosed
EP-0649409-A1 VINYL ARENAS HAVING RETINOID-LIKE ACTIVITY ALLERGAN, INC. (US) 1995-04-26 EP disclosed
WO-1993025530-A2 VINYL ARENAS HAVING RETINOID-LIKE ACTIVITY ALLERGAN, INC. (US) 1993-12-23 WO disclosed
WO-1993025529-A1 3-FLUOROPYRIDINES, METHOD OF PREPARING THEM AND THEIR USE IN LIQUID-CRYSTAL MIXTURES HOECHST AKTIENGESELLSCHAFT (DE) 1993-12-23 WO disclosed
EP-0573878-A1 3-fluoropyridines, process for their preparation and their use in liquid crystal mixtures HOECHST AKTIENGESELLSCHAFT (DE) 1993-12-15 EP disclosed